Condition
Refractory High Grade B-Cell Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Refractory High Grade B-Cell Lymphoma clinical trials that are recruiting, at sites in 2 countries (most in United States (4), France (1)). By phase: Phase 2 (3), Phase 1 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Refractory High Grade B-Cell Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Odronextamab as bridging therapy for relapsed or refractory large B‑cell lymphoma before CAR‑T | Phase 2 | Seattle, Washington | Recruiting | Jan 20, 2025 |
| Golcadomide treatment after CAR T-cell therapy for aggressive large B-cell lymphoma | Phase 2 | Créteil and 12 other locations | Recruiting | Feb 21, 2024 |
| Treatment for relapsed or refractory diffuse large B-cell lymphoma | Phase 2 | Duarte, California | Recruiting | Jan 5, 2023 |
| Genetically engineered CAR T-cells for treating certain blood cancers | Phase 1 | Columbus, Ohio and 1 other locations | Recruiting | Jun 14, 2022 |
| CAR-T therapy for HIV-related aggressive B-cell lymphoma | Phase 1 | Duarte, California and 6 other locations | Recruiting | Oct 14, 2021 |
All recruiting trials (5)
-
Odronextamab as bridging therapy for relapsed or refractory large B‑cell lymphoma before CAR‑T
This trial tests whether giving odronextamab before CAR‑T cell therapy can keep disease under control in adults with relapsed or refractory large B‑cell lymphomas.
-
Golcadomide treatment after CAR T-cell therapy for aggressive large B-cell lymphoma
This study is testing if golcadomide can help people with aggressive large B-cell lymphoma stay in remission after they receive CAR T-cell therapy.
-
Treatment for relapsed or refractory diffuse large B-cell lymphoma
This study is testing a new combination of two treatments for people with relapsed or hard-to-treat diffuse large B-cell lymphoma to see if it helps them respond better and live longer.
-
Genetically engineered CAR T-cells for treating certain blood cancers
This study is testing a new type of treatment using specially modified immune cells to see if they can help people with certain blood cancers that haven't responded to other treatments.
-
CAR-T therapy for HIV-related aggressive B-cell lymphoma
This study is testing a new CAR-T therapy to see if it can safely help people with HIV-related aggressive B-cell lymphoma that hasn't responded to other treatments.
Related topics
Quick answers
How many Refractory High Grade B-Cell Lymphoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (4 trials), France (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.